SAT-443 Osilodrostat Has No Clinically Relevant Effect on the Pharmacokinetic (PK) Profile of a Monophasic Oral Contraceptive in Healthy Females Receiving Cortisol Replacement Therapy

Background: Osilodrostat, a potent oral 11β-hydroxylase inhibitor, is in Phase 3 development for endogenous Cushing’s syndrome (CS). As CS occurs mostly in females of childbearing age, it is important to determine the effect of osilodrostat on oral contraceptives (OCs). We report the effect of multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Breitschaft, Astrid, Tauchmanova, Libuse, Han, Kevin, Atkinson, Susan, Nauwelaerts, Heidi, Sengupta, Tirtha, Zic, Ivanka, Burgmeyer, Lisa, Pedroncelli, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552051/
http://dx.doi.org/10.1210/js.2019-SAT-443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552051/
http://dx.doi.org/10.1210/js.2019-SAT-443

Ejemplares similares